Oncology

Keytruda demonstrated statistically significant improvements in overall survival.

Pembrolizumab shows statistically significant improvements in overall survival and objective response rate in cancer treatment.

Southern Italy tomato varieties demonstrated a potential role against typical neoplastic features.

Nanoparticle precisely delivers tumor antigens to immune cells while stimulating immunity.

Breast cancer incidence has climbed among Asian Americans, while diagnosis rates among other groups have trended downward.

Substantial increase in breast cancer incidences among Koreans, South Asians, and Southeast Asians.

Tracking unstable chromosomes allows scientists to peer into the evolution of NSCLC.

Keytruda found to improve the overall response rate in pediatric and adult patients with cHL.

Pembrolizumab approved for adults and pediatric patients with refractory classical Hodgkin lymphoma.

Chronic hepatitis B virus is still a problem in many parts of the world and the United States, despite the availability of a vaccine.

Top news of the week in oncology and cancer drug development.

Keytruda improved overall response rate and progression free survival in NSCLC.

Pembrolizumab (Keytruda) in combination with pemetrexed and carboplatin treats patients with metastatic non-squamous non-small cell lung cancer.

Oral cancer treatments provide new opportunities for improved overall survival rates, but patients are increasingly responsible for higher out-of-pocket costs as they self-manage their therapy.

Legendary NBA star Kareem-Abdul Jabbar faced his toughest battle after being diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia.

Specialty pharmacists are uniquely positioned to help with the treatment of breast cancer.

With the rise of oral oncolytics, the ability to educate patients while providing resources to monitor compliance and adverse-effect management becomes even more critical. 

The final days of the Obama administration witnessed the federal government launch several initiatives seeking to advance the battle against cancer. 

Emerging oncology therapies, often made available to patients through specialty pharmacies, continue to be a key driver and focus of the business.

Patients diagnosed with colorectal cancer are at a higher risk for mood disorders such as depression, bipolar disorder, and anxiety.

Top news of the day from across the health care landscape.

Kisqali Femara Co-Pack only requires 1 co-payment.

Kisqali Femara Co-Pack (ribociclib tablets; letrozole tablets) treats hormone receptor-positive, human epidermal growth factor receptor-2 negative breast cancer in post-menopausal patients.

The Kisqali Femara Co-Pack is the only approved combination pack that includes 2 prescription drugs used to treat breast cancer.

Regular low-dose aspirin use associated with a lower risk of breast cancer.

Suppressing MAFK pathway in tumor cells may slow spread of aggressive breast cancer.

World Health Organization reports lack of uptake of hepatitis treatments.

Low-dose aspirin may help women reduce their risk of developing breast cancer, a new study published in Breast Cancer Research has suggested.